Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome

What Was Tested

Researchers studied Exenatide in this randomized controlled trial publication.

Obesity and insulin resistance (IR) are common features of polycystic ovary syndrome (PCOS).

This study aimed to explore the therapeutic effects of exenatide once-weekly (QW) combined with MET on body weight, as well as metabolic and endocrinological parameters in overweight/obese women with PCOS.

Who Took Part

PubMed tags the participants as women only.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.

The timeline in the abstract includes 12 weeks.

What Was Measured

PubMed files the paper under topics including Exenatide, Metformin, Obesity, Overweight and Polycystic Ovary Syndrome.

What This Means in Plain Language

The paper is a randomized study of Exenatide over 12 weeks.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (Chinese medical journal), a journal based in China.

More context: the Exenatide compound page, all human trials.